search
Back to results

Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

Primary Purpose

Hypercholesterolemia, Disease, Dyslipidemias

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Placebo
Dietary portfolio
Sponsored by
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypercholesterolemia focused on measuring hypercholesterolemia, dietary portfolio, soy protein, LDL-C, lipoprotein subclasses, nopal, chia seed, functional foods

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and women
  • Body mass index (BMI) 25 to ≤ 39.9 kg/m2
  • Adults between 20 and 60 years of age
  • Total cholesterol levels of >200mg/dL in serum
  • LDL-C levels ≥130mg/dL ≤190mg/dL
  • Literate subjects
  • Signature of informed consent

Exclusion Criteria:

  • Subjects with diabetes
  • Diseases that produce obesity or diabetes
  • Cardiovascular events
  • Weight-loss of ≥ 3kg on the preceding months to the study
  • Catabolic diseases such as cancer and acquired immunodeficiency syndrome
  • Pregnancy and breastfeeding
  • Positive Smoking
  • Pharmacological treatment including:

Antihypertensive drugs Hypoglycemic agents Statins, fibrates or any other treatment for dyslipidemia Steroid medications Chemotherapy, immunosuppressants, and radiotherapy Anorexigens or other medication to induce weight-loss

  • Subjects with high cardiovascular risk
  • Subjects with symptomatic digestive pathologies

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Experimental

    Arm Label

    Placebo (P)

    Dietary Portfolio (DP)

    Arm Description

    The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.

    The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.

    Outcomes

    Primary Outcome Measures

    Low density lipoprotein- cholesterol (LDL-C)
    Plasma total LDL-C (mg/dl)
    Lipoprotein subclasses
    High density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) subclasses (small medium and large) as measure by nuclear magnetic resonance spectroscopy (NMR) in μmol/L.

    Secondary Outcome Measures

    Total cholesterol
    Plasma total cholesterol (mg/dL)
    Triglycerides
    Plasma triglycerides (mg/dL)
    High density lipoprotein cholesterol (HDL-C)
    Plasma HDL cholesterol (mg/dL)
    Apolipoprotein B
    Change in apolipoprotein B in
    Apolipoprotein A
    Change in apolipoprotein A in plasma
    Total/ high density lipoprotein cholesterol (HDL-C) ratio
    Change in total/ high density lipoprotein cholesterol (HDL-C) ratio
    Apolipoprotein B/Apolipoprotein A ratio
    Change in Apolipoprotein B / Apolipoprotein A ratio

    Full Information

    First Posted
    October 31, 2019
    Last Updated
    November 4, 2019
    Sponsor
    Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04148976
    Brief Title
    Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia
    Official Title
    Effect of Dietary Intervention on LDL-C Levels and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    February 28, 2013 (Actual)
    Primary Completion Date
    December 18, 2018 (Actual)
    Study Completion Date
    December 18, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The primary aim of the present study was to elucidate the effect of a combination of functional foods on the low-density lipoprotein cholesterol (LDL-C) levels and on the distribution of the lipoprotein subclasses in subjects with hypercholesterolemia. To accomplish the latter, subjects that met the inclusion criteria and had mild hypercholesterolemia (Total cholesterol >200mg/dL, and LDL-C >130mg/dL <190 mg/dL) were recruited for double-blind, parallel, controlled dietary intervention study. After two weeks of dietary standardization with an isocaloric diet, subjects were randomized and allocated to either placebo or a dietary portfolio treatment for two months. The secondary endpoints were the size of the different lipoprotein subclasses, total cholesterol levels, high density -lipoprotein cholesterol (HDL-C) levels, apolipoprotein B, triglycerides, total/HDL-C ratio, apolipoprotein B/apolipoprotein A ratio, and anthropometric measurements.
    Detailed Description
    The present work took place at the Department of Physiology of Nutrition at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ). The study followed a randomized, controlled, double-blind, parallel design encompassing five visits. On the first visit, volunteers were screened for eligibility criteria. Subjects that met the inclusion criteria were then invited to a second visit. Herein, volunteers received a thorough explanation of the experimental maneuver, as well as the overall objectives of the study. Thereafter, subjects who agreed to participate signed a consent form. Upon agreement, assessment of habitual dietary intake and physical activity was obtained by 24-hour dietary recalls, food frequency questionnaire (FFQ), and by the International Physical Activity Questionnaire (IPAQ), respectively. Additionally, anthropometric measurements and blood samples were registered and collected. Then, volunteers underwent dietary standardization for two weeks with isocaloric diets (LSFD), which followed the National Cholesterol Education Program (NCEP) , Adult Treatment Panel III (ATP III) criteria. That is, 50-60% carbohydrates, 15% protein, 25-35% fat,<7% saturated fat,≤ 200mg of dietary cholesterol, 20-35g of fiber, and 2000mg/d of sodium. On the third visit, subjects were randomly allocated to either LSFD plus placebo or an LSFD plus the dietary portfolio (DP). Of note, the prescribed diets were matched to the volunteers' habitual caloric intake -considering the energy provided by the placebo or DP- to avoid variability of the endpoint variables due to weight-loss. The DP and placebo provided 200kcal; the DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The organoleptic characteristics and packaging were similar between treatments. Subjects were instructed to consume two packets per day, preferably with breakfast and dinner. The content of each packet (30g of product) was dissolved in 250-300ml of water. Volunteers followed the given treatment for two consecutive months, during which two follow-up visits took place. Blood samples, anthropometric characteristics, and blood pressure were obtained in all visits. Compliance to diet, placebo, and DP was assessed with 24-hour dietary recalls, 3-day dietary records, and with the number of empty packets returned on the corresponding visits.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypercholesterolemia, Disease, Dyslipidemias
    Keywords
    hypercholesterolemia, dietary portfolio, soy protein, LDL-C, lipoprotein subclasses, nopal, chia seed, functional foods

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    This study had two stages. In the first stage, subjects underwent dietary standardization with low saturated fat dietary treatments (LSFD) designed according to NCEP, ATP III criteria, and that provided the same amount of energy as that of the habitual diet of the volunteers, as assessed by 24-hour dietary recalls. In the second stage, subjects were randomly allocated to two different treatments, 1) LSFD plus placebo or, 2) LSFD plus dietary portfolio. Subjects were instructed to consume two packets of the corresponding treatment a day dissolved in 250-300 ml of water before breakfast and dinner for two consecutive months.
    Masking
    ParticipantInvestigator
    Masking Description
    The DP and placebo were packed in identical form and appearance. The treatment was provided in sealed boxes to the participants by an individual external to the study, but who performed the randomization. Furthermore, the researcher and the volunteer were unaware of the allocation of treatment.
    Allocation
    Randomized
    Enrollment
    62 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo (P)
    Arm Type
    Placebo Comparator
    Arm Description
    The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
    Arm Title
    Dietary Portfolio (DP)
    Arm Type
    Experimental
    Arm Description
    The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo
    Intervention Description
    A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Dietary portfolio
    Intervention Description
    A mixture of functional foods divided into 30g individual packets.
    Primary Outcome Measure Information:
    Title
    Low density lipoprotein- cholesterol (LDL-C)
    Description
    Plasma total LDL-C (mg/dl)
    Time Frame
    Change in total LDL-C after 2.5 months of treatment
    Title
    Lipoprotein subclasses
    Description
    High density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) subclasses (small medium and large) as measure by nuclear magnetic resonance spectroscopy (NMR) in μmol/L.
    Time Frame
    Change in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatment
    Secondary Outcome Measure Information:
    Title
    Total cholesterol
    Description
    Plasma total cholesterol (mg/dL)
    Time Frame
    Change in total cholesterol after 2.5 months of treatment
    Title
    Triglycerides
    Description
    Plasma triglycerides (mg/dL)
    Time Frame
    Change in triglycerides after 2.5 months of treatment
    Title
    High density lipoprotein cholesterol (HDL-C)
    Description
    Plasma HDL cholesterol (mg/dL)
    Time Frame
    Change after 2.5 months of treatment
    Title
    Apolipoprotein B
    Description
    Change in apolipoprotein B in
    Time Frame
    Change after 2.5 months of treatment
    Title
    Apolipoprotein A
    Description
    Change in apolipoprotein A in plasma
    Time Frame
    Change after 2.5 months of treatment
    Title
    Total/ high density lipoprotein cholesterol (HDL-C) ratio
    Description
    Change in total/ high density lipoprotein cholesterol (HDL-C) ratio
    Time Frame
    Change after 2.5 months of treatment
    Title
    Apolipoprotein B/Apolipoprotein A ratio
    Description
    Change in Apolipoprotein B / Apolipoprotein A ratio
    Time Frame
    Change after 2.5 months of treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Men and women Body mass index (BMI) 25 to ≤ 39.9 kg/m2 Adults between 20 and 60 years of age Total cholesterol levels of >200mg/dL in serum LDL-C levels ≥130mg/dL ≤190mg/dL Literate subjects Signature of informed consent Exclusion Criteria: Subjects with diabetes Diseases that produce obesity or diabetes Cardiovascular events Weight-loss of ≥ 3kg on the preceding months to the study Catabolic diseases such as cancer and acquired immunodeficiency syndrome Pregnancy and breastfeeding Positive Smoking Pharmacological treatment including: Antihypertensive drugs Hypoglycemic agents Statins, fibrates or any other treatment for dyslipidemia Steroid medications Chemotherapy, immunosuppressants, and radiotherapy Anorexigens or other medication to induce weight-loss Subjects with high cardiovascular risk Subjects with symptomatic digestive pathologies
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nimbe Torres y Torres, PhD
    Organizational Affiliation
    INCMNSZ
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    22090467
    Citation
    Guevara-Cruz M, Tovar AR, Aguilar-Salinas CA, Medina-Vera I, Gil-Zenteno L, Hernandez-Viveros I, Lopez-Romero P, Ordaz-Nava G, Canizales-Quinteros S, Guillen Pineda LE, Torres N. A dietary pattern including nopal, chia seed, soy protein, and oat reduces serum triglycerides and glucose intolerance in patients with metabolic syndrome. J Nutr. 2012 Jan;142(1):64-9. doi: 10.3945/jn.111.147447. Epub 2011 Nov 16.
    Results Reference
    background
    PubMed Identifier
    31451009
    Citation
    Guevara-Cruz M, Flores-Lopez AG, Aguilar-Lopez M, Sanchez-Tapia M, Medina-Vera I, Diaz D, Tovar AR, Torres N. Improvement of Lipoprotein Profile and Metabolic Endotoxemia by a Lifestyle Intervention That Modifies the Gut Microbiota in Subjects With Metabolic Syndrome. J Am Heart Assoc. 2019 Sep 3;8(17):e012401. doi: 10.1161/JAHA.119.012401. Epub 2019 Aug 27.
    Results Reference
    background
    PubMed Identifier
    18377791
    Citation
    Jenkins DJ, Josse AR, Wong JM, Nguyen TH, Kendall CW. The portfolio diet for cardiovascular risk reduction. Curr Atheroscler Rep. 2007 Dec;9(6):501-7. doi: 10.1007/s11883-007-0067-7.
    Results Reference
    background
    PubMed Identifier
    19204302
    Citation
    Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 Feb 24;119(7):931-9. doi: 10.1161/CIRCULATIONAHA.108.816181. Epub 2009 Feb 9.
    Results Reference
    background
    PubMed Identifier
    19917453
    Citation
    Torres N, Guevara-Cruz M, Granados J, Vargas-Alarcon G, Gonzalez-Palacios B, Ramos-Barragan VE, Quiroz-Olguin G, Flores-Islas IM, Tovar AR. Reduction of serum lipids by soy protein and soluble fiber is not associated with the ABCG5/G8, apolipoprotein E, and apolipoprotein A1 polymorphisms in a group of hyperlipidemic Mexican subjects. Nutr Res. 2009 Oct;29(10):728-35. doi: 10.1016/j.nutres.2009.09.013.
    Results Reference
    background
    PubMed Identifier
    14988441
    Citation
    Ascencio C, Torres N, Isoard-Acosta F, Gomez-Perez FJ, Hernandez-Pando R, Tovar AR. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr. 2004 Mar;134(3):522-9. doi: 10.1093/jn/134.3.522.
    Results Reference
    background
    PubMed Identifier
    25132122
    Citation
    Lopez-Romero P, Pichardo-Ontiveros E, Avila-Nava A, Vazquez-Manjarrez N, Tovar AR, Pedraza-Chaverri J, Torres N. The effect of nopal (Opuntia ficus indica) on postprandial blood glucose, incretins, and antioxidant activity in Mexican patients with type 2 diabetes after consumption of two different composition breakfasts. J Acad Nutr Diet. 2014 Nov;114(11):1811-8. doi: 10.1016/j.jand.2014.06.352. Epub 2014 Aug 12.
    Results Reference
    background
    PubMed Identifier
    30266575
    Citation
    Medina-Vera I, Sanchez-Tapia M, Noriega-Lopez L, Granados-Portillo O, Guevara-Cruz M, Flores-Lopez A, Avila-Nava A, Fernandez ML, Tovar AR, Torres N. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019 Apr;45(2):122-131. doi: 10.1016/j.diabet.2018.09.004. Epub 2018 Sep 25.
    Results Reference
    background
    PubMed Identifier
    33932799
    Citation
    Vazquez-Manjarrez N, Guevara-Cruz M, Flores-Lopez A, Pichardo-Ontiveros E, Tovar AR, Torres N. Effect of a dietary intervention with functional foods on LDL-C concentrations and lipoprotein subclasses in overweight subjects with hypercholesterolemia: Results of a controlled trial. Clin Nutr. 2021 May;40(5):2527-2534. doi: 10.1016/j.clnu.2021.02.048. Epub 2021 Mar 6.
    Results Reference
    derived

    Learn more about this trial

    Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

    We'll reach out to this number within 24 hrs